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The tremendous success story of modern medicine is mostly a his-
tory of success in fighting infections. At the same time, however, 
noncommunicable diseases like cancer, metabolic and neurodegen-
erative diseases, psychological disorders, autoimmune diseases and 
allergies, have risen. Allergies have become downright endemic in 
industrialized parts of the world, and incidences are still increasing 
in developing countries. The rise in prevalence of allergy spectrum 
diseases (allergic rhinitis, asthma, food allergies, urticaria, atopic ec-
zema and anaphylaxis) has been attributed to a so- called western-
ized life style. This has spawned the original hygiene hypothesis and 
the concept of allergies as not only genetic, but also environmental 
diseases. The impact that environment and life style have on aller-
gies is illustrated by the finding that immediately after the German 
reunification, lifetime prevalence of allergic diseases differed sig-
nificantly in eastern and western federal countries of Germany[1] 
but progressively evened out within only 30 years.[2] Today, allergic 
sensitizations are almost equally frequent in both parts of Germany. 
According to a nationwide survey from 2008- 2011, nearly half of 
the German population is sensitized against at least one allergen, ca. 
30% to at least one inhalant allergen,[3] and ca. 20% of adults suffer 
from at least one allergy.[4] This dramatic short- term development 
cannot be attributed to a drift in gene pool of the population. It has 
sense.
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Allergies are usually referred to as type I hypersensitivity reactions against innocu-
ous environmental antigens, characterized by a Th2/IgE- dominated inflammation. 
They can manifest themselves in various organs, such as skin, gastrointestinal and 
respiratory tract, and comprise diseases as diverse as allergic rhinitis and conjunctivi-
tis, bronchial asthma, oral allergy syndrome, food allergy, urticaria and atopic ec-
zema, but also anaphylactic shock. Within the last decades, there was a significant 
global increase in allergy prevalence, which has been mostly attributed to changes in 
environment and lifestyle. But which, among all factors discussed, are the most rel-
evant, and what are the mechanisms by which these factors promote or prevent the 
development of allergic diseases? To answer this, it is necessary to go back to the two 
key questions that have occupied allergy researchers for the last decades: Firstly, 
what makes an allergen an allergen? Secondly, why are more and more individuals 
affected? Within the last decade, we have made considerable progress in answering 
these questions. This review gives an overview over scientific progress in the field, 
summarizes latest findings and points out future prospective and research needs.
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Two master questions have dominated allergy research within 
the last decade. The first question is: what makes an allergen an 
allergen? And the second question: what makes more and more 
people become allergic? Have the allergens become more abun-
dant or more “aggressive” due to environmental cofactors? Or is 
the rise in prevalence rather due to changes in host factors, such 
as altered life style, nutritional habits, medication use or higher 
psychological stress?
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Before discussing the role of environmental factors in allergy, it is 
necessary to first consider the host that these factors act on. It has 
long been known that the predisposition to develop an allergic dis-
ease is to some extent an inheritable trait. Early linkage analyses 
identified loci on chromosomes 5 and 11, containing the IL9 and 
FCERB genes and the IL4 gene cluster, as relevant to atopy and 
asthma.[5] With the rising of the era of genomics, knowledge of the 
genetics behind allergic diseases advanced a great deal. Especially, 
genome- wide association studies (GWAS) have identified single 
nucleotide polymorphisms (SNPs) in a large number of genes as-
sociated with an elevated risk to develop allergies. The picture as 
a whole, however, is difficult to catch. This is explained by the fact 
that allergy spectrum diseases are complex, often heterogeneous 
and always multifactorial. Moreover, they manifest themselves in 
different organs, which explains that some genetic markers as-
sociated with asthma are also found associated with nonallergic 
chronic lung diseases like COPD,  whereas other markers associ-
ated with atopic eczema are associated with chronic inflammatory 
skin diseases.[8,9] The typical “allergic triad”,[10] consisting of atopic 
eczema, allergic rhinitis and asthma, is observed in many but not all 
patients. Those patients typically present with food allergy and at-
opic eczema in early childhood and progress to respiratory allergy 
and asthma in later life. This shows on the one hand that a high de-
gree of relatedness exists between allergy spectrum diseases. On 
the other hand, asthma and atopic eczema are each by themselves 
highly heterogeneous diseases, different clinical phenotypes of 
which are commonly referred to as “endotypes”.[11–13] The exact 
definition of endotypes, and the role of allergic sensitization in 
defining these endotypes, remains a matter of scientific debate. 
At least for asthma, several intermediate phenotypes exist, all of 
which could be linked with a different set of genetic markers.[14] 
Nevertheless, meta- analyses have identified a number of genes 
that have been reproduced in several independent cohorts as being 
associated with atopy, sensitization and allergy spectrum diseases. 
Among the top hits are genes for Th2/ILC2- associated and pro-
IL10, TNFA, IL33, TSLP and RANTES) and their receptors (IL4RA, 
IgE receptor (FCER1A, FCER1B), genes of the MHC II gene cluster 
(HLA- DRB1, HLA- DQB1), genes of the epidermal differentiation 
complex (FLG, SPINK5) and innate pattern recognition receptor 
genes (CD14, TLR7, TLR9 and S100A7).  The complexity of 
the picture ensues from the fact that some of these genetic mark-
ers are linked with atopy in general, others with elevated serum 
IgE levels, allergic rhinitis, asthma of various types, atopic eczema, 
or with combinations. Since “allergy” is a trait governed by multi-
ple genes, a combination of different genetic markers gives rise 
to different degrees of predisposition, or predisposes to develop 
certain types of allergies but not others. Given the heterogeneity 
in allergen sources and the fact that different sensitization pro-
files to inhalative allergens exist, it is well conceivable that we will 
come up with different endotypes of allergic rhinitis in the future, 
defined not so much by clinical phenotype but rather by different 
aetiology, and associated with different susceptibility genes.
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When assessing environmental factors in allergy, we next have to 
continue by considering the obvious: the allergens. Allergens are the 
crucial environmental factors—without them, there is no allergy.
Are there “typical” allergens? Allergenic proteins are highly het-
erogeneous. In the past, considerable effort has been put in the 
identification of common structural features of allergens. Mast cells 
are activated if membrane- bound high- affinity IgE receptors spiked 
with IgE molecules are cross- linked by allergens. This process is fa-
cilitated when allergens contain repetitive or linear epitopes for IgE 
antibodies.[17] Repetitive linear IgE epitopes are a structural feature 
of some but not of all allergens. Others, like the major dog allergen 
Can f 1 bind to IgE via conformational epitopes.[18] Without activa-
tion of FceRI, there is not mast cell activation and thus no allergy. 
This simple notion gave rise to the idea of designing hypoallergenic 
proteins that bind to but do not cross- link the high- affinity FceRI. 
Other groups used bioinformatics approaches to identify common 
structural features of allergenic proteins. Such a study revealed 
that only 5% of all protein families grouped by structural features 
contain allergens.[19] However, it remained impossible to predict the 
allergenic potential of a given protein based alone on its structural 
determinants.
What is it then that makes an allergen an allergen? This ques-
tion is especially relevant when considering the potential of a given 
protein to elicit a Th2- skewed T cell response, which is prerequisite 
to an IgE- dominated antibody response. Factors discussed to confer 
allergenic potential to a protein are as unspecific as low molecular 
weight, stability against proteolytic degradation, dosage and route 
of exposure.[20] That antigens entering the body via the oral route 
tend to be tolerated has been known for long. The phenomenon 
is used in murine models of induced peripheral tolerance[21] and in 
oral immunotherapy (sublingual immunotherapy; SLIT). A straight-
forward explanation is the fact that the oral mucosa is populated 
by oral Langerhans cells (oLCs).[22,23] These epithelial dendritic cells 
are highly tolerogenic due to their dense expression of inhibitory 
                
costimulatory B7 family proteins (B7- H1, B7- DC). Upon ligation of 
toll- like receptor 4 (TLR-4), oLCs tend to differentiate naïve CD4+ T 
cells into regulatory T cells (Treg).[24] This feature is exploited in new 
generation immunotherapy preparations, which contain the small 
molecule adjuvant monophosphoryl- lipid A (MPLA), a TLR-4 ligand 
derived from Staphylococcus minnesota that inhibits lower cytotox-
icity than LPS.[25]
This brings us to the key role of the innate immune system in 
allergenicity. Pathogen- associated molecular patterns (PAMPs) or 
danger- associated molecular patterns (DAMPs) are critical in the 
decision- making process of whether a given antigen is tolerated or 
whether it sensitizes the individual, that is elicits a Th2- dominated 
immune response. A seminal finding pointing towards that direc-
tion was that Der p 2, a major allergen of house dust mite, acts as a 
molecular mimic of MD- 2, which, together with LPS, makes up the 
ligand for TLR- 4.  Likewise, Fel d 2, a major allergen from cat sa-
liva, has been shown to bind to LPS, and enhanced binding of the 
complex to TLR- 4 has been suggested.[27] Finally, a minor allergen 
of house dust mite, Der p 13, was recently demonstrated to induce 
TLR- 2 signalling, which could contribute to the strong sensitizing po-
tential of dust mite particles.[28]
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For major pollen proteins, such intrinsic adjuvant activity is rare. 
Instead, pollen releases other cofactors that are not allergenic by 
themselves but are encountered by the immune system of the 
respiratory tract together with the allergens. These molecules are 
thought to facilitate allergic sensitization towards pollen proteins. 
Such cofactors include proteases, NADPH oxidases and lipid media-
tors.[29] We recently demonstrated that pollen extracts are inducers 
of the NLRP3 inflammasome in UV- B- primed human primary ke-
ratinocytes.[30] Activation of MD2 was shown to be involved in aller-
gic sensitization towards ragweed pollen extract in a murine allergy 
model involving repeated intranasal instillations.[31] In this study, 
a pollen extract prepared from lyophilized pollen of a commercial 
source was used and was tested free of LPS by LAL- assay. However, 
purified ragweed pollen allergen was not tested in the mouse model. 
To our own experience, a general feature of highly purified recom-
binant pollen proteins, such as rBet v 1 and rAmb a 1, is that they 
have virtually no sensitizing potential in murine models.[32] In con-
trast, if the same proteins are applied within their natural “matrix,” 
that is within an aqueous pollen extract, allergic sensitization results 
even in the absence of external adjuvants such as alum. Recently, 
however, a highly immunogenic Amb a 1 isoform was described to 
potently sensitize mice in the absence of adjuvant, presumably due 
to its stability to endolysosomal degradation in dendritic cells.[33]
The near future is likely to reveal many more mechanisms how 
single allergens induce innate immune signalling. The challenge in 
understanding the puzzle of allergic sensitization will be to integrate 
existing information about allergens from diverse sources, to exactly 
determine which pathways have necessarily to be involved, and in 
what target cells.
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We have learned that among the top susceptibility genes for al-
lergy are genes involved in innate immune signalling, such as CD14 
and TLRs. Furthermore, the quest of defining a “typical allergen” 
has led to the key finding that activation of innate immune signal-
ling, for example via TLRs or the inflammasome, is prerequisite to al-
lergic sensitization. It now becomes clear how the “westernized life 
style” could impact on the predisposition to develop allergic diseases. 
Epidemiological studies suggest that there are harmful as well as pro-
tective environmental and life style factors that act mainly in early 
childhood and adolescence, sometimes in utero. Beneficial factors in-
clude growing up in a rural environment with contact to farm animals 
(“farming effect”),[34,35] nutrition rich in dietary fibres and a high food 
diversity,  and early contact with siblings or peers.[40] A feature 
common to all these environmental factors is that they favour the 
-
gans that is of the skin and the mucosa of the respiratory, urogenital 
and gastrointestinal tract.[41,42] The early interaction of commensal 
and environmental microbiota, the so- called old friends,[43] with the 
-
nition receptors, seems to be instrumental to the adjustment of the 
innate immune system. This interaction likely establishes a “set point” 
for the activation of pattern recognition receptors and downstream 
signalling pathways, which influences immune homoeostasis and re-
action capacity later in life. Harmful environmental and life style fac-
tors, in contrast, include obesity and lack of physical exercise,  
a diet rich in industrially processed foods, growing up as singlet in an 
urban home with an overall reduced microbial diversity and possibly 
exposure to antibiotics.[41,43,47] All these factors are associated with 
a decreased diversity of environmental microbes and a more or less 
pronounced dysbiosis on the barrier organs of the body.[48] This, in 
turn, leads to an altered set point of the innate immune system in 
early childhood, which facilitates loss of peripheral tolerance and the 
development of hypersensitivity later in life.[49]
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Anthropogenic air pollution and the composition of inhaled bioaero-
sols can influence the risk for developing allergic diseases, mainly of 
the airways. Traffic- related air pollution, such as diesel exhaust par-
ticles, NOx and ozone, but also indoor pollutants such as cigarette 
smoke and volatile organic compounds of other sources, have direct 
adverse effects on the airways of exposed individuals. By prim-
ing airway inflammation, for example via inflammasome pathway 
                 
activation, anthropogenic air pollutants aggravate pulmonary in-
flammation to allergen challenge.[50] Epidemiological studies reveal 
a correlation between living near to high- traffic roads and increased 
odds for developing asthma.[51] Prenatal exposure to maternal smok-
ing seems to predispose for the development of allergic asthma.[52] 
On the other hand, there are also beneficial aerosols. The beneficial 
farming effect has mostly been attributed to raw cow milk consump-
tion,[53] but also the inhalation of immune modulatory plant- derived 
compounds from cowshed dust could be protective.[54] A recent 
study that compared different farming and nonfarming homes in 
the German state of Bavaria pointed out the possible importance of 
environmental microbes. In this study, dust samples were collected 
Proximity to the nearest farm as well as a broader bacterial diver-
sity in the dust samples was linked to a higher degree of protection 
against asthma and atopy in the children.[55] This is in line with the in-
triguing findings of a seminal study in which two different northern 
American cohorts from Hutterite and Amish people, both practic-
ing a farming life style, were compared in terms of asthma and al-
lergy prevalence, peripheral blood eosinophil counts and house dust 
composition.  Amish people, who live in close proximity to their 
animals and practice a traditional way of farming, had low preva-
lence of atopy and low blood eosinophil counts. The dust samples 
collected in their homes were rich in bacterial LPS and were found 
to be protective in a mouse model of asthma. Hutterites, in contrast, 
who practiced industrial farming, had comparably high allergic sen-
sitization rates as a northern American control cohort. Dust samples 
collected from Hutterite homes contained low levels of bacterial LPS 
and failed to confer protection against asthma in the mouse model.
Stays in alpine environments have historically been applied to 
support recovery of patients from chronic lung conditions in Europe. 
The famous lung sanatorium in Davos, Switzerland, setting of Thomas 
hospital mainly for asthmatics but also for patients suffering from 
atopic eczema. Moderate altitude seems to be a mediating factor of 
this environmental regime, possibly due to an overall reduced airborne 
allergen burden.[57] Recent clinical evidence gathered from two trials 
on adolescents staying in the Davos rehabilitation hospital points out a 
beneficial effect of short- term stays in moderate altitude on asthma[58] 
and difficult- to- treat atopic eczema. The latter specifically points out 
a role of the alpine environment, since the short- term outcome in the 
Davos group was superior to that of a control group who stayed in a 
hospital in the Netherlands. The beneficial effect on disease activity 
[59]
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Allergens are environmental antigens and are as such subject to 
modification by environmental factors. Pollen- producing plants, in 
specific, react to biotic and abiotic stressors by inducing secondary 
metabolites, such as lipid mediators, and host- defense proteins, some 
of which are allergenic. Birch trees growing at sites with chronically 
elevated ambient ozone levels induced the major allergen Bet v 1 and 
chemotactic lipid mediators in pollen, which resulted in increased al-
lergenic potency. Furthermore, pollen grains might not be sterile but 
carry microbes that elicit, in vitro, T cell responses via activation of 
dendritic cells.  Indeed, pollen of birch trees and grasses harbours 
specific microbial communities, a pollen- specific “microbiome”.  
Intriguingly, the diversity of pollen- associated microbiota was found 
reduced in pollen from birch trees located at sites with elevated 
ambient NO2 levels. This implies that anthropogenic environmental 
stressors, such as air pollutants, negatively affect human health by 
more than one mechanism: either directly, by priming airway inflam-
mation, or indirectly, by enhancing the immune- stimulatory or aller-
genic potential of plant pollen. Finally, also climate change has to 
be considered as an influence factor for the allergenicity of plant 
pollen and fungal allergens. Heavy rainfalls, high humidity episodes 
and thunderstorms might occur more frequently in parts of the 
world due to local climate change. Especially, thunderstorms have 
been shown to go along with atmospheric peaks in highly respirable 
subpollen particles  and fungal spores,  which are discussed as 
causatives of thunderstorm asthma. Earlier onset of plant flower-
ing and higher pollen peaks have already been observed in some 
regions of Europe.  Additionally, changes in local climate favour 
the spreading of a highly allergenic neophyte, Ambrosia artemisiifo-
lia (ragweed), in parts of Europe. Ragweed pollen is small and upon 
inhalation is deposited in the lower airways. They are highly cross- 
allergenic to the native weed Artemisia vulgaris (mugwort)  and 
have shown to induce symptoms in conjunctival challenges of pa-
tients sensitized to Artemisia pollen.  This means that even without 
relevant numbers of genuine sensitizations to ragweed, as presently 
found for Southern Germany,  we have to face the occurrence of 
“new,” potentially severe respiratory allergies to ragweed pollen in 
large parts of Europe.[70] Under climate change scenarios, progres-
sive spreading of stable ragweed plant populations and concomitant 
increases in pollen burden across large parts of Europe is predicted 
even for the near future.[71] In a recently published survey in patients 
with chronic lung diseases and a tourist cohort, both staying in an 
alpine Bavarian region, the overall propensity to perceive the risk of 
climate change- related adverse health effects was positively corre-
lated with symptom severity in both, allergic patients and tourists.[72] 
Apart from stressing the importance of psychological modifiers in 
allergy, this shows that measures to limit adverse health effects of 
climate change should be taken and awareness should be raised.
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Clinical studies on allergy are amongst the studies with the most pro-
nounced placebo effects. The extent to which psychological factors, 
such as general well- being or perceived stress level, influence allergic 
                
symptom perception is indication for a largely unappreciated patho-
physiological component in allergy: neuroendocrine and neuroimmuno-
logical mechanisms. A lot of detail knowledge on cellular and molecular 
level exists, for instance on how hormones of the HPA axis, neurotrans-
mitters and neuropeptides impact on T cells,[73] specifically on cytokine 
production and T helper cell differentiation.[74–77] In atopic eczema pa-
tients, numbers of physical interactions between cutaneous mast cells 
and neuronal fibres were increased in lesional as compared to nonle-
sional skin and correlated with itch and SCORAD.[78] -
edge on the neuroimmunology in allergy is mostly sporadic. Insight from 
in vivo allergy models is very limited. One mouse model combined social 
disruption stress with allergic sensitization to Aspergillus fumigatus.[79] In 
this model, social disruption increased the allergic airway inflammation 
induced by allergen challenge. This was paralleled by reduced glucocor-
ticoid sensitivity and by impaired function of the glucocorticoid receptor 
in splenocytes and lung tissue. Another model combining social disrup-
tion with OVA sensitization also found aggravating effects of social stress 
on allergic inflammation, which was attributed to an over- activation of 
the HPA axis and reduced glucocorticoid sensitivity.[80] Data from epide-
miological and (sporadic) human clinical studies, however, indicate that 
psychosocial factors are indeed relevant. The strongest evidence so far 
comes from studies on atopic eczema. In a German mother- child cohort, 
maternal levels of perceived chronic stress, anxiety and depression dur-
ing pregnancy correlated with prevalence of atopic eczema symptoms 
in the offspring at 2 years of age.[81] A recent study from China on two 
large mother- baby dyads found that maternal depression and anxiety 
during pregnancy increased the odds for atopic eczema in the offspring 
at 1 year of age.[82] In a Danish prospective cohort, self- reported job 
strain of mothers during pregnancy increased the risk for atopic eczema 
in their 7- year old children.[83] Authors of a smaller mother- child birth 
panel study based in Taiwan even suggest that levels of nerve growth 
factor (NGF) in chord plasma and maternal plasma might be a better 
predictor of paediatric atopic eczema than IgE levels.[84] Finally, hypore-
sponsiveness of the HPA axis to stress appears to be associated with 
atopy in humans.
Taken together, both epidemiology and clinical practice point out 
the need to better understand neuroimmunological mechanisms in-
volved in the pathophysiology of allergic diseases. What is missing 
so far is the big picture. A concerted research approach, applying 
combinations of epidemiology, clinical trials, mouse models and pri-
mary human cell culture systems will be needed. Due to their strong 
psychological component, allergic diseases have the potential to 
become model disease in the field and to shed light into the blurry 
semi- darkness of neuroimmunology.
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The human host is more or less susceptible to allergic diseases by 
means of individual genetic background. This genetic background 
consists in several tens to several hundreds of more or less rel-
evant genes, each present in two specific allelic variants, and is 
subject to modification by both, beneficial and harmful environ-
mental and life style factors. Chronic exposure to inhalant pollut-
ants, psychosocial stress, an unhealthy diet or a lack of physical 
exercise induce epigenetic changes in some of the many suscep-
tibility genes for allergy. This altered expression pattern is then 
transmitted to the next generation (for overview, see Figure 1). 
Such complex gene- gene and gene- environment interactions have 
been extensively described for other frequent noncommunicable 
diseases, such as cardiovascular, metabolic and neurodegenera-
tive diseases or cancer. The logic of the interplay between genetic 
background and environmental influence factor becomes evident 
by previous studies on effects of environmental exposure in popu-
lations that were stratified by genetic background. Such studies 
revealed single alleles of the genes for CD14,[87] TLR2, TLR-4 and 
[88] that rendered their carriers susceptible to the beneficial 
Such interactions typically showed a clear dose effect of the pro-
tective allele, with homozygous allele carriers profiting more than 
heterozygous carriers.
Allergies are complex diseases, influenced by genetic, 
environmental and life style factors. Many genes can confer 
susceptibility to allergic diseases. Typically, the contribution of each 
single gene is small, and several genes contribute to the disease 
phenotype (gene- gene interactions). Environmental and life style 
factors modify the expression of genes via epigenetic mechanisms, 
which means these modifiers can affect subsequent generations 
(environment- gene interactions). Priming of the innate immune 
This, in turn, affects immune homoeostasis and predisposition to 
hypersensitivity in the adult (environment- host interaction). Finally, 
anthropogenic pollutants and climate change- related factors exert 
their negative effects on human health either directly, by enhancing 
tissue inflammation and increasing comorbidities (environment- host 
interactions), or indirectly, by modifying allergen carriers, as shown 
for pollen- producing plants (environment- environment interactions)
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Allergies are among the most frequent of noncommunicable dis-
eases. Because they are not considered classical “killers” like can-
cer or cardiovascular diseases, their clinical and societal relevance 
is high. Also, mortality due to fatal asthma attacks and anaphylaxis 
-
lergy research has advanced considerably within the last two dec-
ades. The most challenging puzzles in basic allergy research, what 
makes an allergen an allergen, and what makes people increasingly 
allergic, are on the verge of being solved. Allergy spectrum diseases 
have served as important models for uncovering the role of early 
life innate immune priming by environmental and host microbiota 
and understanding the interplay between genetic susceptibility 
and environmental factors. Lessons learned from allergy research 
will help to better understand the pathobiology of other complex, 
chronic noncommunicable diseases, such as diabetes, autoimmunity, 
neurodegenerative diseases, and even cancer. The understanding 
of how harmful and beneficial environmental factors impact on the 
overall risk for allergic diseases will motivate people to adjust their 
life style in order to minimize individual risks. Integrated information 
from GWAS, combined with data from gene- environment interac-
tion studies, will advance precision medicine to predict whether and 
how a given individual will benefit from an environmental regime 
or medication and to tailor adjuvants for enhanced allergen- specific 
immunotherapy regimes. Finally, the strong psychological compo-
nent of allergies should be regarded as unique chance for clinical 
and laboratory researchers to study psycho- /neuro- immunological 
pathomechanisms that, if understood thoroughly on the cellular and 
molecular level, could be exploited as adjuvant therapy in the symp-
tomatic and causal treatment of various diseases.
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